LNSR LENSAR, Inc.

Nasdaq Surgical & Medical Instruments & Apparatus DE CIK: 0001320350
AI RATING
SELL
72% Confidence

Investment Thesis

LENSAR exhibits a critical disconnect between reported net income ($36.3M) and negative operating cash flow (-$4.3M), indicating the majority of profits stem from non-operating items rather than core business operations. The company is burning cash while showing negative FCF margin (-32.4%), suggesting the current earnings quality is unsustainable for a medical device manufacturer with only $13.4M quarterly revenue.

Strengths

  • + Revenue growth of 13.1% YoY demonstrates market traction
  • + Positive operating income ($2.2M) and operating margin (16.7%) in core business
  • + No long-term debt and current ratio of 2.38x provide balance sheet stability

Risks

  • ! Operating cash flow is negative (-$4.3M) while company reports large net income, indicating non-operating gains distorting profitability
  • ! Free cash flow is -$4.4M with -32.4% FCF margin, revealing business is not self-sustaining on cash basis
  • ! Gap of $34.1M between operating income ($2.2M) and net income ($36.3M) suggests reliance on one-time items, likely unsustainable
  • ! Weak interest coverage ratio (1.7x) limits financial flexibility
  • ! Small revenue base ($13.4M) for medical device sector with uncertain path to cash profitability

Key Metrics to Watch

Financial Metrics

Revenue
13.4M
Net Income
36.3M
EPS (Diluted)
$0.00
Free Cash Flow
-4.4M
Total Assets
66.2M
Cash
12.5M

Profitability Ratios

Gross Margin N/A
Operating Margin 16.7%
Net Margin 270.6%
ROE 336.7%
ROA 54.9%
FCF Margin -32.4%

Balance Sheet & Liquidity

Current Ratio
2.38x
Quick Ratio
1.08x
Debt/Equity
0.00x
Debt/Assets
62.9%
Interest Coverage
1.67x
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: 2026-05-10T07:34:28.029893 | Data as of: 2026-03-31 | Powered by Claude AI